Possible consequence of Trump’s trade war with China


  • Letters
  • Friday, 03 May 2019

IN July 2018, the Food and Drug Administration (FDA) of the United States announced a recall of the anti-hypertensive angiotensin receptor blocker (ARB) valsartan because of contamination with a cancer-causing nitrosamine, N-nitrosodimethylamine (NDMA).

Initially affecting only one Chinese factory, the recall was then expanded and emulated by other regulatory bodies on companies and factories all over the world.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Letters

Enough checks and balances
Solutions to overcrowded schools
New account a valuable tool
Reduce medication waste by redistributing it to those in need
Well done to our Malaysian badminton players for a gallant effort
All for sustainable tourism
Redefining success and education
History as a solution to national unity
BPA-free yet still toxic?
In solidarity with US campus protests

Others Also Read